TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy: a Randomized Double-blind Trial (ERIKA Study)
Brief Summary: Study Objective: To assess the value of Rivaroxaban for the prevention of venous thromboembolism (VTE) after knee arthroscopy (KA) taking the placebo as standard of reference.

Study Population: Patients undergoing therapeutic KA at the study Centers, irrespective of the type and duration of the procedure, will be eligible for the study.

Study Design: Multicenter, randomized, double blind superiority, phase II trial comparing two arms:

* (R-7d) Rivaroxaban (10 mg od os) for 7 days
* (PL-7d) Placebo for 7 days.

Follow-up: 3-month period after the randomization

Standard of Reference:Placebo will be the standard of reference in accordance to international guidelines

Study length May 2012-December 2012

Total patients number: 500 patients

Primary Efficacy End-Point: Occurrence in the 3-month period after the randomization of at least one of the following events, objectively proven (by means of CCDU; multi-slice chest TC-angio; autopsy, if necessary, or clinical ground):

* All-cause mortality
* Symptomatic VTE
* Asymptomatic proximal DVT

Secondary Efficacy End-point:

• Combined incidence of all DVT plus symptomatic PE

Primary Safety End-point: Incidence of major bleedings.

Secondary Safety End-point: Overall incidence of bleeding


Options:
A: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
B: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
C: Arm Label: DRY group; Type: ACTIVE_COMPARATOR; Interventions: Other: Dry sheet Therapeutic body wraps | Arm Label: WET Group; Type: EXPERIMENTAL; Interventions: Other: WET sheet Therapeutic body wraps | Intervention Type: OTHER; Name: Dry sheet Therapeutic body wraps; Assigned to Arm(s): DRY group | Intervention Type: OTHER; Name: WET sheet Therapeutic body wraps; Assigned to Arm(s): WET Group
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Catheter related infection is the third cause of nosocomial infection in ICUs. Most of them are avoidable and can be prevent by improving aseptic practices during catheter insertion and maintenance. Indeed, the main route of catheter contamination for short-term catheters is the insertion site. Consequently, the quality of skin disinfection is the most effective preventive measure to reduce the incidence of these infections.

This aim of the present study is to compare four strategies of skin disinfection to determine whether a 2% alcoholic solution of chlorhexidine acts better than 5% alcoholic povidone iodine in reducing catheter infection and to assess whether a detersion phase prior to disinfection reduces catheter colonization as compared with no detersion.


Options:
A: Arm Label: Oct/Alc; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol | Arm Label: Alc; Type: ACTIVE_COMPARATOR; Interventions: Drug: 74% Ethanol with 10% 2-propanol | Intervention Type: DRUG; Name: 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol; Assigned to Arm(s): Oct/Alc | Intervention Type: DRUG; Name: 74% Ethanol with 10% 2-propanol; Assigned to Arm(s): Alc
B: Intervention Type: DRUG; Name: Skin disinfection; Assigned to Arm(s): N/A
C: Arm Label: PVI paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: PVI scrub and paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: Chlorhexidine paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: chlorhexidine scrub and paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Intervention Type: PROCEDURE; Name: skin disinfection prior catheter insertion; Assigned to Arm(s): Chlorhexidine paint, PVI paint, PVI scrub and paint, chlorhexidine scrub and paint
D: Arm Label: 3-days dressing frequency/CHX sponge; Type: EXPERIMENTAL; Interventions: Device: Chlorhexidine Sponge (Biopatch TM) | Arm Label: 7-days dressing frequency/CHX sponge; Type: EXPERIMENTAL; Interventions: Device: Chlorhexidine Sponge (Biopatch TM), Behavioral: 7-day catheter dressing frequency | Arm Label: 3-days dressing frequency/No CHX sponge; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 7-days dressing change/No CHX sponge; Type: EXPERIMENTAL; Interventions: Behavioral: 7-day catheter dressing frequency | Intervention Type: DEVICE; Name: Chlorhexidine Sponge (Biopatch TM); Assigned to Arm(s): 3-days dressing frequency/CHX sponge, 7-days dressing frequency/CHX sponge | Intervention Type: BEHAVIORAL; Name: 7-day catheter dressing frequency; Assigned to Arm(s): 7-days dressing change/No CHX sponge, 7-days dressing frequency/CHX sponge

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids
Brief Summary: Phase III, multicentre, randomized, double-blind, parallel group, long-term study investigating the efficacy and safety of the 5mg and 10mg doses of PGL4001 for the treatment of uterine myoma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Ulipristal acetate (PGL4001) 5mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 5 mg | Arm Label: Ulipristal acetate (PGL4001) 10mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 10 mg | Intervention Type: DRUG; Name: PGL4001 5 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 5mg | Intervention Type: DRUG; Name: PGL4001 10 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 10mg
C: Arm Label: Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: Inert capsule; Type: PLACEBO_COMPARATOR; Interventions: Drug: Inert Capsule | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Mifepristone | Intervention Type: DRUG; Name: Inert Capsule; Assigned to Arm(s): Inert capsule
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo, drug free period | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin, drug free period | Intervention Type: DRUG; Name: PGL4001, placebo, drug free period; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin, drug free period; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)
Brief Summary: Very premature infants with a large ductus, selected by an early echocardiogram, will receive either ibuprofen or placebo before 12 hours of life. Follow-up will include repeated echocardiograms and cranial ultrasound at 36 hours, 14 days and 36 weeks of postconceptional age. The primary outcome will be survival without cerebral palsy at years.


Options:
A: Arm Label: Small ductus; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Large ductus ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Arm Label: Large ductus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Large ductus ibuprofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Large ductus placebo
B: Arm Label: Paracetamol effect on ductus; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Arm Label: Paracetamol effect on pain; Type: EXPERIMENTAL; Interventions: Drug: paracetamol, Drug: 0.45 % saline solution | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain | Intervention Type: DRUG; Name: 0.45 % saline solution; Assigned to Arm(s): Paracetamol effect on ductus, Paracetamol effect on pain
C: Arm Label: early ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Early ibuprofen | Arm Label: Late Ibuprofen expectant group (placebo); Type: OTHER; Interventions: Other: Late ibuprofen expectant group (placebo) | Intervention Type: DRUG; Name: Early ibuprofen; Assigned to Arm(s): early ibuprofen | Intervention Type: OTHER; Name: Late ibuprofen expectant group (placebo); Assigned to Arm(s): Late Ibuprofen expectant group (placebo)
D: Arm Label: Oral ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ibuprofen | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Oral ibuprofen; Assigned to Arm(s): Oral ibuprofen | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Normal saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)
Brief Summary: Very premature infants with a large ductus, selected by an early echocardiogram, will receive either ibuprofen or placebo before 12 hours of life. Follow-up will include repeated echocardiograms and cranial ultrasound at 36 hours, 14 days and 36 weeks of postconceptional age. The primary outcome will be survival without cerebral palsy at years.


Options:
A: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen
B: Arm Label: Small ductus; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Large ductus ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Arm Label: Large ductus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Large ductus ibuprofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Large ductus placebo
C: Arm Label: Infant treated with high dose ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Infant treated with high dose ibuprofen
D: Arm Label: ibuprofen group; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: paracetamol group; Type: EXPERIMENTAL; Interventions: Drug: paracetamol | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen group | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): paracetamol group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS
Brief Summary: The purpose of this study is to determine whether weekly text-messages improve retention in care of HIV-infected individuals who are not yet eligible for antiretroviral therapy (ART).


Options:
A: Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-help materials, Drug: nicotine patch, Behavioral: Counseling | Arm Label: Automated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Self-help materials, Drug: nicotine patch, Other: Smartphone-delivered automated treatment | Intervention Type: BEHAVIORAL; Name: Self-help materials; Assigned to Arm(s): Automated Treatment, Standard Treatment | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Automated Treatment, Standard Treatment | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Standard Treatment | Intervention Type: OTHER; Name: Smartphone-delivered automated treatment; Assigned to Arm(s): Automated Treatment
B: Arm Label: Phone counseling intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-delivered mobile phone counseling intervention, Behavioral: Treatment as Usual | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Nurse-delivered mobile phone counseling intervention; Assigned to Arm(s): Phone counseling intervention | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Phone counseling intervention, Treatment as Usual
C: Arm Label: WelTel SMS service; Type: EXPERIMENTAL; Interventions: Behavioral: WelTel SMS service | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WelTel SMS service; Assigned to Arm(s): WelTel SMS service
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Video treatments | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Video treatments | Intervention Type: BEHAVIORAL; Name: Video treatments; Assigned to Arm(s): Control, Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS
Brief Summary: The purpose of this study is to determine whether weekly text-messages improve retention in care of HIV-infected individuals who are not yet eligible for antiretroviral therapy (ART).


Options:
A: Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-help materials, Drug: nicotine patch, Behavioral: Counseling | Arm Label: Automated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Self-help materials, Drug: nicotine patch, Other: Smartphone-delivered automated treatment | Intervention Type: BEHAVIORAL; Name: Self-help materials; Assigned to Arm(s): Automated Treatment, Standard Treatment | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Automated Treatment, Standard Treatment | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Standard Treatment | Intervention Type: OTHER; Name: Smartphone-delivered automated treatment; Assigned to Arm(s): Automated Treatment
B: Arm Label: WelTel SMS service; Type: EXPERIMENTAL; Interventions: Behavioral: WelTel SMS service | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WelTel SMS service; Assigned to Arm(s): WelTel SMS service
C: Arm Label: Individualized, interactive SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Individualized, interactive short messaging intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Individualized, interactive short messaging intervention; Assigned to Arm(s): Individualized, interactive SMS
D: Arm Label: Kilkari; Type: EXPERIMENTAL; Interventions: Other: Kilkari | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Kilkari; Assigned to Arm(s): Kilkari

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS
Brief Summary: The purpose of this study is to determine whether weekly text-messages improve retention in care of HIV-infected individuals who are not yet eligible for antiretroviral therapy (ART).


Options:
A: Arm Label: Connected to Care; Type: EXPERIMENTAL; Interventions: Behavioral: Connected to Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Connected to Care; Assigned to Arm(s): Connected to Care
B: Arm Label: Text Message; Type: EXPERIMENTAL; Interventions: Other: Text Message | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Text Message; Assigned to Arm(s): Text Message
C: Arm Label: WelTel SMS service; Type: EXPERIMENTAL; Interventions: Behavioral: WelTel SMS service | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WelTel SMS service; Assigned to Arm(s): WelTel SMS service
D: Arm Label: Cell-phone assisted; Type: EXPERIMENTAL; Interventions: Device: Cell-phone | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cell-phone; Assigned to Arm(s): Cell-phone assisted

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS
Brief Summary: The purpose of this study is to determine whether weekly text-messages improve retention in care of HIV-infected individuals who are not yet eligible for antiretroviral therapy (ART).


Options:
A: Arm Label: General health information; Type: PLACEBO_COMPARATOR; Interventions: Other: general health information | Arm Label: Influenza and general health information; Type: ACTIVE_COMPARATOR; Interventions: Other: influenza and general health information | Intervention Type: OTHER; Name: influenza and general health information; Assigned to Arm(s): Influenza and general health information | Intervention Type: OTHER; Name: general health information; Assigned to Arm(s): General health information
B: Arm Label: social networking on mobile phone; Type: EXPERIMENTAL; Interventions: Other: social networking on mobile phone | Arm Label: no social networking on mobile phone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: social networking on mobile phone; Assigned to Arm(s): social networking on mobile phone
C: Arm Label: Control; Type: N/A; Interventions: Behavioral: Control | Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
D: Arm Label: WelTel SMS service; Type: EXPERIMENTAL; Interventions: Behavioral: WelTel SMS service | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WelTel SMS service; Assigned to Arm(s): WelTel SMS service

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness-Based Cognitive Therapy (MBCT) and Cognitive Behavioral Therapy (CBT) for Depression in Patients With Diabetes: a Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether mindfulness-based cognitive therapy (MBCT)and cognitive behavioral therapy (CBT)are effective in reducing depressive symptoms in patients with diabetes.


Options:
A: Arm Label: MBCT; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Cognitive Therapy (MBCT) | Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Cognitive Therapy (MBCT); Assigned to Arm(s): MBCT | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT
B: Arm Label: Mindfulness-based Addiction Treatment (MBAT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness-based Addiction Treatment, Behavioral: Self-Help guide, Drug: Nicotine Patch | Arm Label: iQuit Mindfully; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based Addiction Treatment, Behavioral: iQuit Mindfully, Behavioral: Self-Help guide, Drug: Nicotine Patch | Intervention Type: BEHAVIORAL; Name: Mindfulness-based Addiction Treatment; Assigned to Arm(s): Mindfulness-based Addiction Treatment (MBAT), iQuit Mindfully | Intervention Type: BEHAVIORAL; Name: iQuit Mindfully; Assigned to Arm(s): iQuit Mindfully | Intervention Type: BEHAVIORAL; Name: Self-Help guide; Assigned to Arm(s): Mindfulness-based Addiction Treatment (MBAT), iQuit Mindfully | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Mindfulness-based Addiction Treatment (MBAT), iQuit Mindfully
C: Arm Label: Mindfulness Based Stress Reduction (MBSR) program; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Healthy Living Course (HLC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducation | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness Based Stress Reduction (MBSR) program | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): Healthy Living Course (HLC)
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Mindful Eating | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindful Eating; Assigned to Arm(s): Experimental

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
Brief Summary: The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.


Options:
A: Arm Label: Alendronate/Alendronate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alendronate, Drug: Placebo to Romosozumab | Arm Label: Romosozumab/Alendronate; Type: EXPERIMENTAL; Interventions: Biological: Romosozumab, Drug: Alendronate, Drug: Placebo to Alendronate | Intervention Type: BIOLOGICAL; Name: Romosozumab; Assigned to Arm(s): Romosozumab/Alendronate | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Alendronate/Alendronate, Romosozumab/Alendronate | Intervention Type: DRUG; Name: Placebo to Romosozumab; Assigned to Arm(s): Alendronate/Alendronate | Intervention Type: DRUG; Name: Placebo to Alendronate; Assigned to Arm(s): Romosozumab/Alendronate
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BA058 80 mcg (abaloparatide); Type: EXPERIMENTAL; Interventions: Drug: BA058 80 mcg | Arm Label: teriparatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: teriparatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BA058 80 mcg; Assigned to Arm(s): BA058 80 mcg (abaloparatide) | Intervention Type: DRUG; Name: teriparatide; Assigned to Arm(s): teriparatide
C: Intervention Type: DRUG; Name: raloxifene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: alendronate (Fosamax); Assigned to Arm(s): N/A

Answer: A